Skip to main content
Clinical Trials/EUCTR2019-004041-32-GB
EUCTR2019-004041-32-GB
Active, not recruiting
Phase 1

The effect of Canagliflozin 300mg, in subjects without diabetes after bariatric surgery, on glucose homeostasis (The CONTROL Study): A proof-of-concept, randomised, open-label, two period crossover study. - The CONTROL Study

niversity of Leicester0 sites24 target enrollmentJuly 13, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Leicester
Enrollment
24
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 13, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity of Leicester

Eligibility Criteria

Inclusion Criteria

  • Age\=18 years old but less than 75 years old
  • Subjects \=1 year after gastric bypass (RYGB) or sleeve gastrectomy (SG)
  • Able to understand written and spoken English
  • Able to give informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 22
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 2

Exclusion Criteria

  • Use of any glucose\-lowering medication (including insulin)
  • Adrenal insufficiency and/or substitution with glucocorticoids
  • ALT \>1\.5 times the upper normal limit
  • Moderate to severe renal impairment (eGFR\=60 ml/min/1\.73m2\)
  • Individuals on loop diuretics
  • Participants with established diagnosis of postural hypotension by their GP
  • Recent active infection (over the last 10 days)
  • Current use of steroids
  • Other bariatric procedure except of RYGB/SG
  • Previous revisional bariatric surgery

Outcomes

Primary Outcomes

Not specified

Similar Trials